...of 4 million shares at $5.50 in a follow-on. Earlier in the month, CymaBay (formerly Metabolex Inc....

...with data expected in 1H15. The compound is a uricosuric agent. Last week, CymaBay (formerly Metabolex Inc....

...before CymaBay announced the amendment, the company would raise $21.1 million. In April, CymaBay (formerly Metabolex Inc....

...amended its follow-on and now plans to sell 3.5 million shares. In April, CymaBay (formerly Metabolex Inc....

...million. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. In April, CymaBay (formerly Metabolex Inc....

...Partners; National Securities Note: CymaBay also plans to transfer its listing to NASDAQ. CymaBay (formerly Metabolex Inc....

...listing to NASDAQ. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. CymaBay (formerly Metabolex Inc....

...of a $10 million loan from Oxford Finance and Silicon Valley. In October, CymaBay (formerly Metabolex Inc....

...two Phase III trials, with initial data expected in 1Q14. Arhalofenate, another URAT1 inhibitor from Metabolex Inc....
...NYSE:JNJ), New Brunswick, N.J. The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. MedImmune LLC , Gaithersburg, Md. Metabolex Inc....

...the next stage of development. The most advanced GPR119 agonists are PSN821 and MBX-2982 from Metabolex Inc....
...Intercept Pharmaceuticals Inc. , New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Metabolex Inc....